Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Asthma Clinical Trial

Official title:

A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00353873
• Other study ID #: SAM104926
• Status: Completed
• Phase: Phase 4
• Start date: November 18, 2005
• Est. completion date: October 26, 2006

Study information

• Verified date: March 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.

Description:

A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100mcg twice daily and fluticasone propionate (FLIXOTIDE™) at a dose of 200mcg twice daily, both delivered via a dry powder inhaler (DISKUS™) for 12 weeks in asthma in children aged 4-11 years not controlled by inhaled corticosteroids alone at medium dose

Recruitment information / eligibility

• Status: Completed
• Enrollment: 506
• Est. completion date: October 26, 2006
• Est. primary completion date: October 26, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 11 Years

Eligibility

Inclusion criteria:

• A documented clinical history of asthma for a period of at least 6 months.

• A documented history (within 12 months of Visit 1) of airway reversibility of = 15% based either on Forced expiratory volume (FEV1) or PEF measured pre and post inhalation of 200 mcg salbutamol. (If no documented history of reversibility exists, patients must demonstrate a =15% reversibility at Visit 1).

• Receiving an inhaled corticosteroid at a medium dose (beclomethasone dipropionate HydroFluoroAlkane (HFA) non fine particle = 400-500 mcg/day or beclomethasone HFA fine particle = 200mcg/day, or budesonide =400 mcg/day or fluticasone = 200 mcg/day (or fluticasone 250mcg/day if subject is taking a 125mcg MDI rather than the 100mcg Diskus), for at least 3 months prior to Visit 1 and at a stable dose for at least 4 weeks prior to Visit 1.

• Able to use the Mini-Wright peak flow meter and subject or parent/guardian had to be able to record the subject's maximum PEF correctly.

• Able to perform FEV1 correctly.

• Subject's guardian/parent able to complete an eDRC on behalf of the subject. The eDRC should be completed by the guardian/parent.

• Able to use a DISKUS™ correctly.

• At least one parent(s)/guardian(s) has to give written informed consent to participate in the study.

At the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:

• not achieved the criteria for the 'Well-controlled' asthma during two or more of the 4 weeks prior to Visit 2.

Exclusion criteria:

• Female subjects who have reached menarche.

• Received any investigational study medication in the 4 weeks prior to Visit 1.

• Experienced a respiratory tract infection in the 4 weeks prior to Visit 1.

• Experienced an acute asthma exacerbation requiring emergency room treatment within 4 weeks or hospitalisation within 12 weeks of Visit 1.

• Any use of oral/parenteral or depot corticosteroid within 12 weeks of Visit 1.

• Any use of long-acting inhaled beta2-agonists or oral beta2-agonists within 4 weeks of Visit 1.

• Any use of leukotriene antagonists or theophyllines within 4 weeks of Visit 1.

• Any known clinical or laboratory evidence of a serious uncontrolled disease (including serious psychological disorders) which is, in the opinion of the investigator, likely to interfere with the study.

• Subjects with a known or suspected hypersensitivity to inhaled corticosteroids, beta2-agonists, or any components of the formulations (e.g. lactose)

• A relative of any of the site staff, including the investigator or study co-coordinator.

• Has previously been entered into this study.

Subjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:

• Pre-bronchodilator FEV1 <60% (assuming that measurement was correctly performed).

• Any change in asthma medication (excluding use of prophylactic study specific salbutamol for prevention of asthma symptoms due to exercise).

• Respiratory tract infection or asthma exacerbation.

• Use of oral, parenteral or depot corticosteroids.

• Emergency visit due to asthma.

• Non-compliance with the completion of the eDRC (i.e. during the 4 week period between visits, non compliance is defined as less than 5 days of completed data within any one week for four weeks - subjects must complete at least 5 days a week for the entire run-in period).

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Fluticasone propionate
200µg twice daily
• Fluticasone propionate/salmeterol
50/100µg twice daily

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Brugge
Belgium	GSK Investigational Site	Brussel
Belgium	GSK Investigational Site	Edegem
Belgium	GSK Investigational Site	Gent
Belgium	GSK Investigational Site	Leuven
Denmark	GSK Investigational Site	Aalborg
Denmark	GSK Investigational Site	Odense
France	GSK Investigational Site	Essey les Nancy
France	GSK Investigational Site	Grasse
France	GSK Investigational Site	Laon
France	GSK Investigational Site	Nimes
France	GSK Investigational Site	Oyonnax
France	GSK Investigational Site	Paris
France	GSK Investigational Site	Paris cedex 15
France	GSK Investigational Site	Rouen
France	GSK Investigational Site	Rouen Cedex
France	GSK Investigational Site	Saint Michel
France	GSK Investigational Site	Tours Cedex 1
France	GSK Investigational Site	Vaux En Velin
France	GSK Investigational Site	Villejuif
Italy	GSK Investigational Site	Foggia	Puglia
Italy	GSK Investigational Site	Napoli	Campania
Italy	GSK Investigational Site	Palermo	Sicilia
Italy	GSK Investigational Site	Perugia	Umbria
Latvia	GSK Investigational Site	Daugavpils
Latvia	GSK Investigational Site	Riga
Latvia	GSK Investigational Site	Riga
Lithuania	GSK Investigational Site	Kaunas
Lithuania	GSK Investigational Site	Taurage
Lithuania	GSK Investigational Site	Vilnius
Netherlands	GSK Investigational Site	Almere
Netherlands	GSK Investigational Site	Beek En Donk
Netherlands	GSK Investigational Site	Den Haag
Netherlands	GSK Investigational Site	Deurne
Netherlands	GSK Investigational Site	Emmen
Netherlands	GSK Investigational Site	Ermelo
Netherlands	GSK Investigational Site	Nieuwegein
Netherlands	GSK Investigational Site	Spijkenisse
Netherlands	GSK Investigational Site	Tiel
Netherlands	GSK Investigational Site	Woerden
Norway	GSK Investigational Site	Drammen
Norway	GSK Investigational Site	Kongsvinger
Norway	GSK Investigational Site	Oslo
Poland	GSK Investigational Site	Bialystok
Poland	GSK Investigational Site	Krakow
Poland	GSK Investigational Site	Lodz
Poland	GSK Investigational Site	Lublin
Russian Federation	GSK Investigational Site	Krasnoyarsk
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Moscow
Russian Federation	GSK Investigational Site	Novokuznetsk
Russian Federation	GSK Investigational Site	Novosibirsk
Russian Federation	GSK Investigational Site	St'Petersburg
Russian Federation	GSK Investigational Site	Syktyvkar
Russian Federation	GSK Investigational Site	Tomsk
Spain	GSK Investigational Site	Almeria
Spain	GSK Investigational Site	Barcelona
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	Madrid
Spain	GSK Investigational Site	San Sebastián
Spain	GSK Investigational Site	Sevilla
Sweden	GSK Investigational Site	Sollentuna
Sweden	GSK Investigational Site	Stockholm
Sweden	GSK Investigational Site	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Belgium,  Denmark,  France,  Italy,  Latvia,  Lithuania,  Netherlands,  Norway,  Poland,  Russian Federation,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population	PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in electronic diary record card (eDRC), performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using analysis of covariance (ANCOVA) adjusted for baseline PEF, country amalgamation, age, sex and treatment.	Baseline; Week 1 up to Week 12
Primary	Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population	PEF is the maximum flow generated during expiration, as measured with a peak flow meter and recorded in eDRC, performed with maximal force and started after a full inspiration. The mean morning PEF measurement was constructed by calculating a simple mean for each participant over the interval Weeks 1 to 12. All PEF measurements were converted to the Wright/McKerow peak flow meter scale for the purposes of analyses. The change from Baseline is then calculated by subtracting the Baseline PEF values from the individual on-treatment values. Baseline was calculated as the mean of the values recorded on the seven days preceding randomization. The analysis was done using ANCOVA adjusted for baseline PEF, country amalgamation, age, sex and treatment.	Baseline; Week 1 up to Week 12
Secondary	Number of Participants Who Achieved 'Totally Controlled' (TC) Asthma	TC asthma is defined as no daily symptoms, no night-time wakening due to asthma, no exacerbations, no rescue salbutamol/albuterol use, no emergency visits, >=80% predicted morning PEF, and no treatment related adverse events enforcing a change in asthma therapy over 7 consecutive days. Number of participants/group who achieved the status of at least TC during the last 8 weeks (wks) of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline pre-bronchodilator Forced Expiratory Volume in one second (FEV1). Asthma control was assessed each week for the last 8 wks of treatment period. Each week was classified as 'TC', 'Well Controlled' (WC), 'Not Controlled' or 'Unevaluable'. A participant was considered to have TC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were TC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.	Week 5 up to Week 12
Secondary	Number of Participants Who Achieved WC Asthma	WC asthma is defined as two or more of symptom score >1 only allowed on <=2 days/week, rescue salbutamol/albuterol use on <=2 days/week and up to a maximum of 4 times per week, >=80% predicted morning PEF daily assessed for 7 consecutive days and all the following criteria: no night-time awakening due to asthma, no exacerbations, no emergency visits, no treatment related adverse events enforcing a change in any asthma therapy. Number of participants/group who achieved the status of at least WC during the last 8 wks of treatment was analyzed using logistic regression, including covariates for sex, age, treatment group, country amalgamation and baseline prebronchodilator FEV1. Each week was classified as 'WC', 'Not Controlled' or 'Unevaluable'. A participant was considered to have WC asthma if they achieved 4/4, 5/5, 6/6, 6/7, 7/8 or 8/8 wks that were WC. 'Unevaluable' classification included participants with less than 4 wks of data during the assessment period.	Week 5 up to Week 12

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.